Key facts
- TRIANA Biomedicines’s last known valuation is $258.0M (Nov 2025).
- It has raised $246.1M across 2 recorded rounds; the latest was Later Stage VC (Series B) ($120.1M) in Nov 2025.
- Notable investors include Lightspeed Venture Partners, Bessemer Venture Partners, RA Capital Management, The Invus Group, Pfizer Ventures — 12 tracked in total.
- TRIANA Biomedicines has filed 3 Form Ds with the SEC since 2022, most recently Dec 2025 ($120.1M sold to 20 investors).
- Status: Privately Held (backing).
Leadership
- Reza MazhariExecutive Officer
- Fatou NdiayeVice President
- Kathleen SeybSenior Vice President
- Marie-Caroline GermaChief Medical Officer
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for TRIANA Biomedicines
Funding rounds
2 roundsAbout TRIANA Biomedicines
Operator of a pharmaceutical company intended to discover and develop molecular glues. The company leverages technology to stabilize pre-existing or create de novo interactions between multiple proteins and alter the fate or functionality of the disease target, enabling healthcare professionals to develop products for a wide range of therapeutic applications.
- Industry
- Discovery Tools (Healthcare)
- Sector
- Healthcare
- HQ
- Lexington, MA, United States
- Founded
- 2019
- Employees
- 50
- Website
- trianabio.com/
- Ownership
- Privately Held (backing)
TRIANA Biomedicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in TRIANA Biomedicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on TRIANA Biomedicines in its N-PORT filings yet. We sweep new filings monthly.